NICE logo

BIMZELX is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.1

NICE recommendation applies to severe disease (PASI ≥ 10 or DLQI > 10) and when the disease has not responded to other systemic treatments, or when they are contraindicated or not tolerated.2

Off
Pharmacists

This page is for Pharmacists with a clinical role who have Medicine Optimisation interests.

UCB are here to support Medicine Optimisation and to provide guidance on how you can implement BIMZELX in your local area.

 

Off
Off

Formulary pack

Image
Formulary pack
Image
Formulary pack

Formulary pack

Despite existing treatment options available, a significant unmet medical need remains for effective and long-lasting therapies for moderate-to-severe psoriasis patients who are candidates for systemic therapy.3,4

Additional biologic treatments for psoriasis can contribute to flexibility for patients for whom existing treatment options may not be suitable.5

This document provides information and guidance to help support your local formulary application for the use of BIMZELX in the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.1

Some sections provide general information which can be used directly in the local formulary pack if applicable, but other sections will require customisation according to the demographics and priorities of your local area.

 

On

Intervention document

Image
Intervention document
Image
Intervention document

Intervention document

Minimising treatment interventions in psoriasis: the place of BIMZELX® (bimekizumab) in therapy

This document is designed to highlight the benefits of BIMZELX as a treatment option for adults with moderate-to-severe psoriasis, due to potential benefits in terms of clinical outcomes, patient experience and service efficiency.

 

On

NICE: Know your rights

Image
NICE: know your rights
Image
NICE: know your rights

NICE: know your rights

This document will help you clarify what your role is in the provision of new treatments that have been approved through the fast track process by NICE.

It will also help answer questions like: What does NICE mean when it recommends a treatment as 'an option'?

 

On

NHS communication

Image
NHS communication
Image
NHS communication

NHS communication

These resources will help you communicate information about BIMZELX to your relevant stakeholders.

 

On

May also be of interest...

Pharmacy podcasts series
Date of preparation: May 2021 | IE-P-CZ-AS-2100041

A series of podcasts discussing;

  • Crisis management - adapting to the new normal and creating Pharmacist networks
  • Safety profile and the role of Pharmacists and commissioning and making a business case
  • Working within the scope of the practice, consultation skills and clinical assessment skills

Presented by:
Ms Kalveer Flora, Ms Anusha Patel, Mr Paresh Parmar, Professor lnderjit Singh, Ms Katy Jackson, Professor Nina Barnett, Ms Hilary McKee

The Pharmacy Podcast Series

Pharmacy podcasts series
Off
On

References

References

  1. Bimzelx Summary of Product Characteristics.
  2. NICE. Final Appraisal Document. Bimekizumab for treating moderate to severe plaque psoriasis. 2021.
  3. Feldman SR, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. American Health & Drug Benefits. 2016b;9(9):504-513.
  4. Kragballe K, et al. Unmet needs in the treatment of psoriasis. European Journal of Dermatology. 2014;24(5):523-532.
  5. Kerdel F, et al. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatologic Therapy. 2015;28(6):390-403.
On

CHALLENGE EXPECTATIONS

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: August 2021
IE-P-BK-PSO-2100060